Ellington Management Group LLC acquired a new position in United Therapeutics Co. (NASDAQ:UTHR) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 6,800 shares of the biotechnology company’s stock, valued at approximately $1,006,000.
Several other institutional investors and hedge funds have also made changes to their positions in UTHR. Quantbot Technologies LP lifted its holdings in shares of United Therapeutics by 537.3% in the 3rd quarter. Quantbot Technologies LP now owns 975 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 822 shares during the last quarter. Focused Wealth Management Inc bought a new stake in shares of United Therapeutics in the 4th quarter worth approximately $139,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of United Therapeutics in the 3rd quarter worth approximately $156,000. SeaCrest Wealth Management LLC bought a new stake in shares of United Therapeutics in the 4th quarter worth approximately $178,000. Finally, JOYN Advisors Inc. bought a new stake in shares of United Therapeutics in the 4th quarter worth approximately $201,000.
United Therapeutics Co. (NASDAQ UTHR) opened at $115.34 on Monday. The company has a quick ratio of 3.01, a current ratio of 3.26 and a debt-to-equity ratio of 0.12. United Therapeutics Co. has a one year low of $107.82 and a one year high of $152.55. The company has a market cap of $4,987.27, a price-to-earnings ratio of 10.51 and a beta of 1.32.
UTHR has been the topic of several analyst reports. ValuEngine raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, December 26th. Zacks Investment Research raised shares of United Therapeutics from a “hold” rating to a “buy” rating and set a $160.00 target price on the stock in a research note on Monday, January 15th. BidaskClub raised shares of United Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, December 6th. Wedbush reaffirmed an “outperform” rating and issued a $232.00 target price (up from $213.00) on shares of United Therapeutics in a research note on Wednesday, December 27th. Finally, Oppenheimer lifted their target price on shares of United Therapeutics to $180.00 and gave the stock an “outperform” rating in a research note on Friday, January 5th. Five equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the stock. United Therapeutics presently has an average rating of “Hold” and a consensus target price of $135.20.
United Therapeutics Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.